Tags

Type your tag names separated by a space and hit enter

Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy.
J Hum Hypertens. 2010 Dec; 24(12):823-30.JH

Abstract

The benefits of valsartan (Val)/hydrochlorothiazide (HCTZ) combination as initial treatment for hypertension were evaluated in a post hoc analysis of an 8-week, double-blind, placebo-controlled, parallel-group trial. The highest dose of Val/HCTZ combination (320/25 mg), component monotherapies (Val 320 mg, HCTZ 25 mg) and placebo were selected for this analysis (N=675, 52.1% men, 68.6% Caucasians, mean age 52.9 years, baseline blood pressure (BP) 150.6/99.1 mm Hg). As soon as 2 weeks after initiation of active therapy, greater BP control rates were observed with Val/HCTZ (320/25 mg) compared with Val (320 mg), HCTZ (25 mg) and placebo. Similar results were observed in subgroups of patients with stage 1 and stage 2 hypertension, as well as in diabetic patients. As baseline BP increased, the probability of achieving mean sitting systolic BP (<140 and <130 mm Hg) and mean sitting diastolic BP control (<90 and <80 mm Hg), determined using a logistic regression model, decreased with all treatments. However, at all levels of baseline BP, the probability of achieving BP control was greater with Val/HCTZ combination. The Val/HCTZ combination was well tolerated with overall incidence of adverse events similar to that observed with monotherapy and placebo. These results support the use of Val/HCTZ combination as initial therapy in hypertensive patients unlikely to achieve BP control with a single agent.

Authors+Show Affiliations

Department of Medicine, Hypertension Research Center, Indiana University School of Medicine, Indianapolis, IN 46202, USA. mweinbe@iupui.eduNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

20182456

Citation

Weinberger, M H., et al. "Achieving Blood Pressure Goal: Initial Therapy With Valsartan/hydrochlorothiazide Combination Compared With Monotherapy." Journal of Human Hypertension, vol. 24, no. 12, 2010, pp. 823-30.
Weinberger MH, Glazer RD, Crikelair NA, et al. Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. J Hum Hypertens. 2010;24(12):823-30.
Weinberger, M. H., Glazer, R. D., Crikelair, N. A., & Chiang, Y. T. (2010). Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. Journal of Human Hypertension, 24(12), 823-30. https://doi.org/10.1038/jhh.2010.17
Weinberger MH, et al. Achieving Blood Pressure Goal: Initial Therapy With Valsartan/hydrochlorothiazide Combination Compared With Monotherapy. J Hum Hypertens. 2010;24(12):823-30. PubMed PMID: 20182456.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Achieving blood pressure goal: initial therapy with valsartan/hydrochlorothiazide combination compared with monotherapy. AU - Weinberger,M H, AU - Glazer,R D, AU - Crikelair,N A, AU - Chiang,Y T, Y1 - 2010/02/25/ PY - 2010/2/26/entrez PY - 2010/2/26/pubmed PY - 2011/3/5/medline SP - 823 EP - 30 JF - Journal of human hypertension JO - J Hum Hypertens VL - 24 IS - 12 N2 - The benefits of valsartan (Val)/hydrochlorothiazide (HCTZ) combination as initial treatment for hypertension were evaluated in a post hoc analysis of an 8-week, double-blind, placebo-controlled, parallel-group trial. The highest dose of Val/HCTZ combination (320/25 mg), component monotherapies (Val 320 mg, HCTZ 25 mg) and placebo were selected for this analysis (N=675, 52.1% men, 68.6% Caucasians, mean age 52.9 years, baseline blood pressure (BP) 150.6/99.1 mm Hg). As soon as 2 weeks after initiation of active therapy, greater BP control rates were observed with Val/HCTZ (320/25 mg) compared with Val (320 mg), HCTZ (25 mg) and placebo. Similar results were observed in subgroups of patients with stage 1 and stage 2 hypertension, as well as in diabetic patients. As baseline BP increased, the probability of achieving mean sitting systolic BP (<140 and <130 mm Hg) and mean sitting diastolic BP control (<90 and <80 mm Hg), determined using a logistic regression model, decreased with all treatments. However, at all levels of baseline BP, the probability of achieving BP control was greater with Val/HCTZ combination. The Val/HCTZ combination was well tolerated with overall incidence of adverse events similar to that observed with monotherapy and placebo. These results support the use of Val/HCTZ combination as initial therapy in hypertensive patients unlikely to achieve BP control with a single agent. SN - 1476-5527 UR - https://www.unboundmedicine.com/medline/citation/20182456/Achieving_blood_pressure_goal:_initial_therapy_with_valsartan/hydrochlorothiazide_combination_compared_with_monotherapy_ L2 - http://dx.doi.org/10.1038/jhh.2010.17 DB - PRIME DP - Unbound Medicine ER -